Sitagliptin in Combination With Metformin and Sulfonylurea
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This study will compare the effect of a new oral agent for type 2 diabetes, sitagliptin, in
comparison to thiazolidinediones as the third-line oral agent, in patients with type 2
diabetes mellitus.